Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5 Febuxostat Usafi wa Kati >99.0% Factory
Ugavi wa Kemikali wa Ruifu Febuxostat Viatu Vinavyohusiana:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2-(3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5
Jina la Kemikali | Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate |
Visawe | Febuxostat ya kati |
Nambari ya CAS | 161797-99-5 |
Nambari ya CAT | RF-PI1122 |
Hali ya Hisa | Katika Hisa, Uwezo wa Uzalishaji Tani 100/Mwaka |
Mfumo wa Masi | C13H13NO3S |
Uzito wa Masi | 263.31 |
Kiwango cha kuyeyuka | 180 ℃ |
Chapa | Ruifu Chemical |
Kipengee | Vipimo |
Mwonekano | Manjano Isiyokolea hadi Unga Nyeupe |
Utambulisho | Na HPLC;Na HNMR |
Kupoteza kwa Kukausha | <0.50% |
Mabaki kwenye Ighition | <0.30% |
Uchafu Mmoja | <0.50% |
Jumla ya Uchafu | <1.00% |
Njia ya Usafi / Uchambuzi | >99.0% (na HPLC) |
Kiwango cha Mtihani | Kiwango cha Biashara |
Matumizi | Kati ya Febuxostat (CAS: 144060-53-7) |
Kifurushi: Chupa, begi ya karatasi ya Alumini, Ngoma ya 25kg/Cardboard, au kulingana na mahitaji ya mteja
Hali ya Uhifadhi:Hifadhi kwenye vyombo vilivyofungwa mahali pa baridi na kavu;Kinga kutoka kwa mwanga na unyevu
Ethyl 2-(4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate (CAS: 161797-99-5) hutumika katika usanisi wa Febuxostat (CAS: 144060-53-7), xanthine oxidase/xanthine dehydrogenase inhibitor.Kutumika kwa ajili ya matibabu ya hyperuricemia na gout ya muda mrefu.40-120 mg/siku ya febuxostat ilithibitishwa kuwa na ufanisi katika kupunguza viwango vya urate katika seramu iliposimamiwa kudhibiti hyperuricemia kwa wagonjwa walio na gout.Fabuxostat iligunduliwa na Teijin Pharmaceuticals na kupewa leseni kwa TAP Pharmaceuticals (ambayo kwa sasa ni sehemu ya Takeda Pharmaceuticals) na iliidhinishwa nchini Marekani kwa ajili ya matibabu ya hyperuricemia kwa wagonjwa wa gout.